Anthera to present BRIGHT-SC data at Kidney Week meeting

Anthera Pharmaceuticals' Phase 2 BRIGHT-SC trial data has been selected as a poster presentation at the 2016 American Society of Nephrology’s Kidney Week Annual Meeting.
The BRIGHT-SC study assess blisibimod’s ability to treat patients with biopsy-proven IgA Nephropathy (IgAN).
“These data provide hope to patients with IgAN, for whom no approved therapy exists, that a targeted therapy may slow disease progression,” Dr. Jonathan Barratt said. Barratt works at the University of Leicester as a reader in the Department of Infection, Immunity & Inflammation; is an honorary consultant nephrologist at Leicester General Hospital; and is head of the postgraduate Specialty School of Clinical Academic Training at Health Education East Midlands.
Friday's presentation in Chicago will be titled “Effects of Blisibomod, a Selective Inhibitor of B-Cell Activating Factor, in Patients with IgA Nephropathy."
“The observations from the BRIGHT-SC study provide clear evidence of blisibimod’s effects on proteinuria, B cells and immunoglobulins which are central to disease pathology, and support the hypothesis that B-cell activation underlies kidney damage. We are pleased to have this opportunity to share these data with the nephrology community,” Anthera Senior Vice President of Medical Sciences Renee Martin said.